Retinoic acid receptors (RARs) are ligand-dependent transcription factors which are members of the steroid/ thyroid hormone receptor gene family. RAR-agonists inhibit the proliferation of many human breast cancer cell lines, particularly those whose growth is stimulated by estradiol (E2) or growth factors. PCR-amplified subtractive hybridization was used to identify candidate retinoidregulated genes that may be involved in growth inhibition. One candidate gene identified was SOX9, a member of the high mobility group (HMG) box gene family of transcription factors. SOX9 gene expression is rapidly stimulated by RAR-agonists in T-47D cells and other retinoidinhibited breast cancer cell lines. In support of this finding, a database search indicates that SOX9 is expressed as an EST in breast tumor cells. SOX9 is known to be expressed in chondrocytes where it regulates the transcription of type II collagen and in testes where it plays a role in male sexual differentiation. RAR pan-agonists and the RARa-selective agonist Am580, but not RXR agonists, stimulate the expression of SOX9 in a wide variety of retinoid-inhibited breast cancer cell lines. RAR-agonists did not stimulate SOX9 in breast cancer cell lines which were not growth inhibited by retinoids. Expression of SOX9 in T-47D cells leads to cycle changes similar to those found with RARagonists while expression of a dominant negative form of SOX9 blocks RA-mediated cell cycle changes, suggesting a role for SOX9 in retinoid-mediated growth inhibition.
Introduction
Retinoids exert profound effects on the growth and differentiation of normal, premalignant and malignant epithelial cells in vivo and in vitro and have shown promise as therapeutic agents in epithelial cancers, acute promyelocytic leukemia, and many other types of malignancies (Agadir et al., 1994; Castaigne et al., 1990; Fenaux, 1993; Hong and Lippman, 1995; Hong and Sporn, 1997; Lotan, 1980; Smith et al., 1992; Sporn and Roberts, 1983) . The effects of retinoids are mediated by receptors which are members of the steroid/thyroid/retinoid nuclear hormone receptor gene family (Mangelsdorf et al., 1990 (Mangelsdorf et al., , 1993 and include the retinoic acid receptors (RARs: RARa, b and g), and the retinoid X receptors (RXRs: RXRa, b and g) (Brand et al., 1988; Giguere et al., 1987; Krust et al., 1989; Mangelsdorf et al., 1993; Mangelsdorf, 1994) .
It has been well established through in vitro studies that retinoids can inhibit the growth of normal mammary epithelial cells (Seewaldt et al., 1997b (Seewaldt et al., , 1999 and breast cancer cell lines (Amos and Lotan, 1990; Lacroix and Lippman, 1980; Lotan, 1980; Marth et al., 1984; Seewaldt et al., 1999) . The anti-proliferative effect of the RAR-agonist, all-trans retinoic acid (RA), in breast cancer cell lines results from inhibition of growth (Seewaldt et al., 1997a,b; Toma et al., 1997; van der Leede et al., 1995) and this effect appears to result from a delay in the transition between the G0-G1 and S phase of the cell cycle (Seewaldt et al., 1997b (Seewaldt et al., , 1999 . Rb, cyclin D and E, cyclin dependent kinases 2, 4, and 6, and their inhibitors p15, p16, p21 and p27 have all been suggested as potential targets for retinoids in normal and malignant breast cells as well as other cell types that are sensitive to retinoidmediated growth inhibition (Langenfeld et al., 1996; Seewaldt et al., 1997b; Zhou et al., 1997) . In addition to mediating cell cycle changes, apoptosis of retinoid responsive cells has been observed by several investigators (Jinno et al., 1999; Mangiarotti et al., 1998; Shao et al., 1995; Sheikh et al., 1995; Teixeira and Pratt, 1997) . Despite the cloning and characterization of the RARs and RXRs, and study of the activities of a variety of retinoid receptor specific ligands in breast cancer cell lines (Arafa et al., 1996 (Arafa et al., , 2000 Desai et al., 2000; Gianni et al., 1996; Willhite et al., 1996) , the fundamental mechanisms of retinoid-mediated growth inhibition remain poorly understood.
To provide insight into the basic mechanisms involved in retinoid-mediated growth inhibition, we used PCR-amplified subtractive hybridization to identify target genes regulated by retinoids in breast cancer cells. In this study we show that RAR pan-agonists and the RARa-selective agonist, Am580, inhibit growth and rapidly stimulate the expression of SOX9 in the retinoid-responsive T-47D and MCF7 breast cancer cell lines. SOX9 is a member of a large family of transcription factors that share homology with the sex determining region Y (SRY) gene product . This group of transcription factors interacts with DNA through a high mobility group (HMG) box, a 79-amino-acid motif originally found in the HMG group of non-histone chromatin components. Human SOX9, a 509-amino-acid protein, contains a transactivation domain at its C-terminus (Sudbeck and Scherer, 1997) that is rich in serine, proline and glutamic acid residues.
SOX9 is expressed in chondrocytes and has been shown to increase the expression of collagen type II by interacting directly with a chondrocyte-specific enhancer sequence of the Proa1(II) collagen gene Lefebvre et al., 1997 . Defects in the SOX9 gene result in campomelic dysplasia, a severe dwarfism syndrome, which affects cartilage-derived structures. High levels of SOX9 mRNA are also expressed in developing testes (Kent et al., 1996) , and individuals with campomelic dysplasia display partial or complete sex reversal, suggesting a role for SOX9 in male sexual differentiation. Search of an EST data base indicates that SOX9 is expressed in breast tumor tissue (EST Accession A622877) and low levels of SOX9 have been reported in estrogen receptor positive (ER + ) T-47D cells . However, the physiologic role of SOX9 in normal and malignant breast cells is unknown. In this study, we present evidence for retinoid regulated expression of SOX9 in breast cancer cells and suggest a possible role for SOX9 in mediating growth inhibition of breast cancer cells by retinoids.
Results
All-trans retinoic acid inhibits estradiol-mediated growth stimulation of ER + T-47D and ZR-75-1 breast cancer cells RAR but not RXR agonists inhibit the growth of many estrogen receptor positive (ER + ) breast cancer cell lines (Fontana et al., 1990; Marth et al., 1984; van der Burg et al., 1993) . We confirmed the RA-mediated growth inhibition of ER + T-47D and ZR-75-1 cells (Figure 1 ). For these studies, T-47D and ZR-75-1 cells were cultured in DMEM supplemented with 10% calf serum. In both cell lines, incubation with 100 nM estradiol (E2) stimulated growth 3 -4-fold compared with untreated cells. In T-47D cells, but not ZR-75-1 cells, 1 mM RA alone inhibited the basal level of cell growth compared with untreated control cells. However, in both cell lines, treatment with both E2 and RA inhibited the growth stimulated by E2 alone. Similar results were obtained with ER + MCF7 cells (data not shown). Since the extent of RA-mediated growth inhibition with E2 was slightly greater in T-47D cells than in ZR-75-1 or MCF7 cells, T-47D cells were selected for further studies to identify retinoid regulated genes.
RAR-but not RXR-agonists inhibit growth of T-47D and MCF7 cells and increase SOX9 gene expression
Numerous studies indicate that the RARs mediate growth inhibition of breast cancer cell lines Fanjul et al., 1996; Fitzgerald et al., 1997; Raffo et al., 2000; Schneider et al., 2000; Seewaldt et al., 1995; Sheikh et al., 1993 Sheikh et al., , 1994 . RAR b and g have been reported to mediate growth inhibition (Fanjul et al., 1996; Raffo et al., 2000; Seewaldt et al., 1995) . RARa also appears to be capable of mediating inhibition of growth and its expression in breast cancer cell lines seems to correlate with retinoid mediated inhibition of growth Fitzgerald et al., 1997; Schneider et al., 2000; Sheikh et al., 1993 Sheikh et al., , 1994 . To identify retinoid-regulated genes that might participate in the inhibition of cell growth, T-47D cells were incubated with 50 nM Am580, a selective RARa agonist at this concentration (Brooks et al., 1996; Gianni et al., 1996) . Am580 was found to inhibit E2-stimulated cell growth of T-47D cells as effectively as RA (data not shown). Treatment of cells with Am580 rather than the natural ligand, RA, offers two advantages. First, RA activates all RARs (RARa, b and g) while 50 nM Am580 is highly selective for RARa-regulated genes. This would eliminate genes selectively regulated by RARb and/or RARg which are unrelated to growth inhibition. Second, RA can be converted in cultured cells to 9-cis retinoic acid, which could lead to changes in RXR-regulated genes that would not be involved in growth inhibition. A library enriched for cDNAs whose expression is increased by Am580 was prepared from total RNA obtained from Figure 1 Retinoic acid inhibits the growth of T-47D and ZR-75-1 breast cancer cells. Cells were cultured for 8 days in DMEM+10% calf serum without supplementation (CONT) or with 100 nM estradiol (E2), 1 mM all trans retinoic acid (RA) or both E2 and RA. Effects on cell growth was indirectly assessed by measuring total protein from each culture dish. Results shown are the average of duplicate cultures control and Am580 treated T-47D cells by PCRmediated subtractive hybridization (Diatchenko et al., 1996) . Differential screening of the enriched cDNA library followed by RNA blot analysis of promising candidates revealed that SOX9 expression is increased by Am580 in T-47D cells. SOX9 mRNA is induced within 5 h and is maintained for at least 20 h of incubation (Figure 2) . A probe for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) confirmed similar RNA loading. The SOX9 cDNA identified in our library corresponds to nucleotides 2851 to 3891 in the 3'-untranslated region of SOX9 mRNA. Sequencing from both ends of the cloned fragment revealed over 98% identity with human SOX9 in the GenBank (data not shown). We also cloned the full-length SOX9 cDNA coding sequence from T-47D cells using PCR and found it to be identical to the human SOX9 sequence deposited in the GenBank and to be transcriptionally active in these cells.
An RNA blot probed with SOX9 cDNA and a GAPDH control, indicated that SOX9 mRNA is increased in T-47D cells treated for 5 or 24 h with 100 nM TTNPB (TTN), a synthetic retinoid that selectively activates RARs but not RXRs (Figure 3 ). In addition, TTNPB also increases SOX9 expression in MCF7 cells. In these experiments, cells were cultured for 48 h in medium containing 10% calf serum supplemented with 10 nM E2 to optimize growth. Cells were then incubated with TTNPB for the final 5 or 24 h before cell lysis and RNA preparation. Although basal expression of SOX9 mRNA appears to be higher in T-47D cells than in MCF7 cells, both cells show an increase in the level of SOX9 mRNA at 5 h which is maintained at 24 h. The electrophoretic position of the identified RNA relative to the 28S and 18S rRNA is consistent with the expected position of SOX9 mRNA (3923 nt). A full length SOX9 cDNA probe (Lefebvre et al., 1997) identified a single RNA species at the same position as that detected by our cloned cDNA fragment (data not shown). Hela cells and LNCaP cells express low levels of an mRNA which electrophoreses to the same position as SOX9 mRNA ( Figure  3 ) but does not change with TTNPB incubation (data not shown).
Breast cancer cells were incubated with various RAR and RXR agonists to determine if stimulation of SOX9 protein is mediated through RAR or RXR. Cells were cultured for 3 days in the presence of 10 nM E2 along with 1 mM RA, 50 nM Am580, 100 nM of TTNPB, or 20 nM of the RXR-specific agonist LGD-100153. SOX9 expression was detected by Western blotting using an antibody raised against human SOX9 . Am580 and TTNPB inhibited growth of T-47D cells (data not shown). In contrast,
LGD 1000153 was without effect, although it is biologically active and could stimulate an RXR CATreporter in these cells (data not shown). . Protein from whole cell extracts were size-separated by SDS -PAGE, transferred to nitrocellulose and analysed by immunoblotting with a SOX9-specific antibody Figure 3 The RAR pan-agonist, TTNPB, increases expression of SOX9 mRNA in MCF7 and T-47D cells. MCF7 or T-47D cells were incubated with estradiol (E2) for a total of 48 h and with TTNPB (TTN) for either 5 or 24 h as indicated prior to preparation of RNA. Northern blotting was as described in Figure 2 3 cells and BT-20 cells are ER 7 cell lines. BT-20 cells are unresponsive to retinoids while SK-BR-3 cells express high levels of RARa and the growth of these cells is inhibited by incubation with RA (Fitzgerald et al., 1997; Schneider et al., 2000) . SK-BR-3 and BT-20 cells were cultured for 3 days with or without 1 mM RA and harvested directly into SDS -PAGE loading buffer. After electrophoresis and transfer to nitrocellulose, Ponceau S staining showed less protein in the lane from RA-treated SK-BR-3 cells due to retinoid mediated growth inhibition. Immunoblotting revealed SOX9 expression only in the RA treated SK-BR-3 cells ( Figure  5a ). SOX9 was not detected in retinoid insensitive ER 
Expression of SOX9 in murine tissues
Since our findings indicate that RAR-agonists stimulate SOX9 expression in breast cancer cells, we sought to determine whether SOX9 is expressed in normal breast tissue in vivo and if RA administration leads to further stimulation. Male and female mice were treated for 4 days with 150 mg of RA and assayed for SOX9 mRNA by PCR in breast and other tissues obtained from treated and control mice. SOX9 mRNA was detected in testis, kidney, and breast tissue from male and female mice ( Figure 6 ). In this experiment, we noticed a slight increase in the SOX9 mRNA in breast and testis obtained from RA treated mice. However, this was not observed in all mice. SOX9 mRNA was also detected in liver (data not shown). SOX9 is known to be required for male sexual differentiation and may play a role in normal testis physiology. Our results raise the possibility that SOX9 may play a role in normal breast physiology as well.
Cell cycle changes in T-47D cells transiently transfected with SOX9
Retinoid-sensitive breast cancer cells have been reported to exhibit a delay in the G0-G1 phase of cell cycle following treatment with RA or other RARagonists Mangiarotti et al., 1998; Offterdinger et al., 1998) . To confirm this, T-47D cells were incubated with 1 mM RA for 48 h followed by flowcytometric analysis of propidium iodide stained cells. RA incubated T-47D cells show an increase in the G0-G1 phase and a decrease in the S phase compared with control cells (Figure 7 ) (7RA: G0-G1=50%, S=33%, G2=17%; +RA: G0-G1=60%, S=24%, G2-M=16%). Since SOX9 expression is increased in T-47D cells incubated with RA, we asked whether transient expression of SOX9 in T-47D cells would induce cell cycle changes comparable to those found with RA. In addition, if stimulation of SOX9 by RA is involved in mediating the growth inhibitory effects of RA, then expression of a dominant negative form of SOX9 would be expected to block the effect of RA on the cell cycle. For these studies, T-47D cells were transfected with either GFP-SOX9 or GFP-SOX9-DN expression vectors. Both GFP-SOX9 proteins localize to the cell nucleus (Figure 8 ). In addition, GFP-SOX9 is transcriptionally active and stimulates a SOX9 reporter gene while GFP-SOX9-DN acts as a dominant negative inhibitor and blocks activation by SOX9 (Figure 9 ). For cell cycle studies, cells were harvested 48 -72 h after transfection and stained with propidium iodide. Cells which did not express GFP-SOX9 ( Figure  10 ) in the transfection (GFP 7 ) exhibited cell cycle parameters similar to untreated T-47D cells (Figure 7) . The percentage of cells in G0-G1, S and G2 in cells expressing GFP-SOX9 ( Figure 10 ) were similar to that found in untransfected T-47D cells treated with RA (Figure 7) . Unlike GFP-SOX9, expression of GFP-SOX9-DN slightly decreased G0-G1 and slightly (Figure 10 and legend) . This finding is consistent with a dominant negative effect of GFP-SOX9-DN on the low basal levels of SOX9 in T-47D cells. In addition, expression of GFP-SOX9-DN blocked the cell cycle changes mediated by RA (Figure 11 ). Cells expressing GFP-SOX9-DN showed no cell cycle changes in response to RA while RA increased the G0-G1 phase and decreased the S phase in cells which did not express GFP-SOX9-DN in the same transfection (Figure 11 ). Although Figure 11 shows complete inhibition of the RA effect on the cell cycle by GFP-SOX9-DN, in other studies the inhibition was not as complete. This may result from differences in the level of expression of GFP-SOX9-DN or reflect different pathways of RA inhibition. Taken together ( Figures  7 -11) , however, our results support the notion that induction of SOX9 by RA plays a role in the cell cycle changes mediated by RA in T-47D cells.
Discussion
The focus of this study was to identify genes which are regulated by retinoids and are potentially involved in retinoid-mediated growth inhibition of breast cancer cells. Although this study reports our findings using PCR subtractive hybridization, we have since confirmed our findings on SOX9 using DNA microarray analysis. We show here that SOX9, which is essential for chondrogenesis (Bell et al., 1997; Bi et al., 1999; Healy et al., 1999; Olney et al., 1999) and male sexual differentiation (Graves, 1998; Hanley et al., 2000; Hawkins, 1995; Koopman, 1999 Koopman, , 2001 , is induced by RAR pan-agonists and an RARa selective agonist in retinoid-inhibited breast cancer cell lines. RAR-agonists have been reported to have divergent effects on the regulation of SOX9 in other cells. SOX9 is stimulated by RA in TC6 cells, a cartilage derived cell line (Sekiya et al., 2000) , while RA transcriptionally represses SOX9 in primary chondrocyte cultures (Sekiya et al., 2001) . Our results also indicate that SOX9 is a retinoid-regulated gene. Analysis of the sequence 500 bp upstream of the SOX9 promoter revealed three potential RARE sites (data not shown).
The expression and regulation of SOX9 in some breast cancer cell lines ( Figure 5 ) suggested the possibility that SOX9 may be expressed in normal breast tissue. To explore this possibility we examined for SOX9 expression in normal mouse mammary tissue as well as the liver, kidney, and testes. SOX9 mRNA was detected in breast, liver, kidney and testes. However, no consistent increase in SOX9 expression was found after RA administration. Since these mice were not retinoid deficient, our results do not exclude the possibility that SOX9 is retinoid regulated in these tissues. In contrast with our finding, Lefebvre et al. (1997) reported expression of SOX9 mRNA in the skin and brain of newborn mice but not in liver and kidney. However, SOX9 has been reported to be expressed in the collecting ducts of the developing kidney (Kent et al., 1996) . The pattern of SOX9 expression in mice could explain, in part, the phenotype found in some patients with campomelic dysplasia. These individuals are usually developmentally delayed and up to one third have been described to have developmental abnormalities of the kidney (Schafer et al., 1996) . The identification of SOX9 mRNA and protein in mammary tissue, suggest that SOX9 may play a role in mammary development, growth, or physiology. Since RA incubation of breast cancer cells stimulates expression of SOX9 and results in a prolongation in the G0-G1 phase of the cell cycle, we were interested in studying cell cycles changes in cells transiently expressing GFP-SOX9. These studies showed a prolongation in the G0-G1 phase and a decrease in the S phase similar to that found in T-47D cells incubated with RAR agonists. GFP-SOX9-DN, lacking the transactivation domain, acts as a dominant negative to inhibit the activity of SOX9 (Figure 9 ). Expression of GFP-SOX9-DN blocked the effect of RA on the cell cycle (Figure 11) suggesting that SOX9 plays a role in mediating the cell cycle changes found in T-47D cells incubated with RA. Our findings are further supported by the recent study of Panda et al. (2001) in CFK2 cells (a rat chondrocytic cell line) stably transfected to express SOX9. Expression of SOX9 resulted in a prolongation in the G0-G1 phase as well as a slight increase in S phase (Panda et al., 2001 ). Although we did not detect an increase in S phase in our studies, the cell cycle changes found with SOX9 in CFK2 cells further support the notion that SOX9 plays a role in mediating the G0-G1 phase changes by RA in responsive breast cancer cells. Although expression of SOX9 leads to growth inhibition of T-47D cells, MDA-MB-435 cells, which are unresponsive to RA, grow rapidly but express basal levels of SOX9. We have not studied the function of SOX9 on the growth of these cells. However, it is possible that these cells may escape SOX9-mediated growth inhibition because: (1) the SOX9 gene contains certain inactivating mutations; (2) certain critical downstream growth controlling genes are unresponsive to SOX9; or (3) the oncogenic pathways responsible for the malignant phenotype bypass putative SOX9 regulated genes.
A number of studies support the notion that RARa is capable of mediating the retinoid inhibition of breast cancer cell growth Fitzgerald et al., 1997; Schneider et al., 2000; Sheikh et al., 1993 Sheikh et al., , 1994 . Our studies are consistent with that finding, and also indicate that the SOX9 gene in T-47D and MCF7 is regulated by RAR and not by RXR. Since SOX9 is a transcriptional activator, it would be of considerable interest to identify the genes in breast cancer cells that are regulated by SOX9. The inhibition of growth of CFK2 cells expressing SOX9 is associated with an increase in the level of the p21 cell cycle kinase inhibitor. However, RA does not appear to consistently alter the level of p21 in breast cancer cell lines, suggesting that SOX9 might mediate its effects through other factors. Factors which have been reported to be modulated by RA in breast cancer cell lines include cyclin D1, cdk2, and Rb (Teixeira and Pratt, 1997) . Whether SOX9 mediates its effects through regulation of one or more of these factors or through yet to be identified SOX9 regulated genes will require further investigation. An alternative possibility is that SOX9 might mediate its effects through the b-catenin-LEF/TCF pathway. Alterations in the b-catenin-LEF/TCF pathway occurs in the development of certain tumors including breast cancer. RA decreases the signaling activity of the b-catenin-LEF/TCF pathway in MCF7 cells, suggesting that regulation of this pathway may be one of the Figure 9 Activity of GFP-SOX9 and GFP-SOX9-DN in T-47D cells. Cells were transfected with the DMTV-(4648)-CAT SOX9 reporter gene along with the indicated plasmids to assess the transcriptional activity of GFP-SOX9 and the dominant negative activity of GFP-SOX9-DN. In addition to GFP-SOX9 (300 ng) and GFP-SOX9-DN (500 ng), cells were also transfected alone or in combination as indicated with vectors expressing GFP (1.3 mg), SOX9 (300 ng), and SOX9-DN (500 ng)
Stimulation of SOX9 and growth inhibition by retinoids O Afonja et al mechanisms by which RA influences development, growth, and cell differentiation (Easwaran et al., 1999) . TCF and LEF-1 are members of the HMG box superfamily, which also includes the SOX proteins (Nagai, 2001) , and exhibit many similarities in structure and function (Giese et al., 1995 (Giese et al., , 1997 Watanabe et al., 2000) . Whether SOX9 influences the activity of this pathway needs further exploration.
In summary, our results indicate that SOX9 is an RAR-regulated gene in breast cancer cell lines. In addition, SOX9 is not only expressed in murine testes, where it plays a role in sexual development, but also in breast tissue suggesting that SOX9 may play a role in the normal physiology of breast development or function. Our findings also support a role for SOX9 in the retinoid-mediated changes in the cell cycle of T-47D cells and other RA-responsive breast cancer cell lines. In future studies we hope to identify the primary target genes regulated by SOX9 in breast cancer cells and to define their role in mediating effects on the growth and biological behaviour of breast cancer cells both in culture and in vivo.
Materials and methods

Cell lines
MCF7, T-47D, ZR-75-1, SK-BR-3, MDA-MB-435, and BT-20 breast cancer cell lines were obtained from American Type Tissue Culture Collection (ATCC; Rockville, MD, USA). All Figure 10 Effect of GFP-SOX9 and GFP-SOX9-DN on the cell cycle of T-47D cells. Cells were transfected with 5 mg of GFP-SOX9 or 5 mg GFP-SOX9-DN for 48 h. Cells were then harvested and stained with propidium iodide. The GFP + cells were separated from the GFP 7 cells and the cell cycle distribution determined by flow cytometry for the GFP + and GFP 7 cells in each transfection. GFP-SOX9: GFP 7 , G0-G1=50%, S=33%, G2-M=17%, GFP + , G0-G1=59%, S=27%, G2-M=14%. GFP-SOX9-DN: GFP
7
, G0-G1=50%, S=32%, G2-M=18%; GFP + , G0-G1=45%, S=36%, G2-M=19%
Stimulation of SOX9 and growth inhibition by retinoids O Afonja et al cell lines were maintained in DMEM (GIBCO-BRL, Life Technologies) supplemented with 10% fetal calf serum.
Ligands all-trans retinoic acid (RA) and Estradiol (E2) were from Sigma.
LGD-100153 and TTNPB (TTN) were obtained from Ligand pharmaceuticals. Am580 was obtained from the Faculty of Pharmaceutical Sciences, University of Tokyo, Japan (Kagechika et al., 1988) . Cells were incubated with either 1 mM RA, 20 nM LGD-100153, 50 nM Am580 or 100 nM TTNPB for 5 -72 h. Estradiol was used at 10 -100 nM.
PCR-amplified subtractive hybridization
PCR-amplified subtractive hybridization reagents were from Clontech and the procedure was carried out as previously described (Diatchenko et al., 1996) . cDNA was prepared from Poly A + RNA isolated from untreated T-47D cells or from T-47D cells incubated for 5, 24 and 48 h with 50 nM Am580. RsaI digested cDNA derived from Am580 treated cells were ligated in separate reactions to different adapters, denatured, and then hybridized with excess RsaI digested cDNA from untreated cells. The two hybridization reactions were then combined and additional denatured cDNA from untreated cells was added. Double stranded cDNAs having different adapters on each strand that anneal during this second hybridization reaction were selectively amplified by PCR using primers complimentary to the two adapter sequences. These double stranded cDNAs represent genes that were expressed uniquely or in excess in the Am580-treated cells and therefore did not fully anneal with the excess cDNA fragments from untreated cells. cDNAs with the same adapter at both ends are not efficiently amplified by PCR due to intrastrand annealing. Following a second round of PCR using primers nested within the adapters, PCR products were cloned in a pGEM-T Easy Vector (Promega) to create a cDNA library expected to be enriched in genes up-regulated by Am580. : without RA, G0-G1=46%, S=38%, G2-M=16%; with RA, GFP 7 , G0-G1=54%, S=31%, G2-M=15%. GFP + : without RA, G0-G1=47%, S=38%, G2-M=15%; with RA, G0-G1=43%, S=38%, G2-M=19%
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Differential screening of the cDNA library
Candidate cDNA clones were selected for further analysis using differential screening. Library clones were PCR amplified using nested primers complementary to the adapter sequences flanking each cloned cDNA. PCR products were arrayed on duplicate nitrocellulose filters. Filters were probed with 32 P-labeled cDNA derived from pooled subtracted PCR products used to create the library or from reverse subtraction PCR products created by subtracting excess cDNA from Am580-treated cells from the cDNA of untreated cells. Clones that hybridized more strongly with the library probe than the reverse subtraction probe most likely represent genes whose expression is increased by Am580. To confirm retinoid regulation of mRNAs, candidate cDNA clones were PCR amplified, labeled with a-32 P-dCTP by random priming, and used to probe slot blots or northern blots containing 0.5 mg of polyA + RNA isolated from untreated or Am580 treated T-47D cells.
Northern blotting
MCF-7 and T-47D cells were cultured as monolayers in 75 cm 2 tissue culture flasks containing DMEM supplemented with 10% fetal calf serum. Cells were exposed to receptor ligands, at concentrations previously mentioned, for 5, 24 or 48 h. Total cell RNA was prepared using the acid guanidium thiocyanate-phenol-chloroform method (Chomczynski and Sacchi, 1987) . Twenty-five micrograms of total RNA was electrophoresed in 0.8% agarose gels containing 0.66 M formaldehyde and transferred to nylon membrane (Osmonics, Westborough, MA, USA) by electroblotting. The membranes were incubated at 688C for 1 h with pre-hybridization buffer (Promega, Madison, WI, USA) containing 0.125 mg/ml of salmon sperm DNA and 0.56SSC. A 1.0-kb RsaI-EcoRI fragment of human SOX9 cDNA was used as a probe and labeled using Rediprime random priming labeling reagents (Pharmacia Biotech, USA) with a-32 P-dCTP (NEN Life Science Products, Boston, MA, USA). Hybridization was at 688C for 18 h in hybridization buffer containing 1610 6 d.p.m./ml of labeled probe. After washing with 26SSC/0.5% SDS for 20 min at room temperature and in 0.26SSC/0.5% SDS for 20 min at 658C, the membranes were exposed to a phosphoimager overnight and the signal obtained quantitated using phosphoimager Storm A20 software (Molecular Dynamics, Amersham Pharmacia Biotech, USA).
Western blotting
Cells were plated in 6-well tissue culture plates at a density of 0.2610 6 cells/well in 5 ml of DMEM medium containing either DMSO (vehicle used to dissolve various retinoid compounds) or the retinoid receptor ligands at concentrations previously mentioned. After 72 h, the medium was removed and the cells were washed twice with PBS. Whole cell extracts were prepared by suspending the cells in lysis buffer (60 mM Tris (pH 7.5), 7.5% glycerol, 5% 2-mercaptoethanol and 1% SDS), and the protein concentration determined using the BCA assay (Bio-Rad Laboratories, Hercules, CA, USA). Extracts containing 25 mg of protein were electrophoresed in 10% polyacrylamide-SDS denaturing gels and transferred to nitrocellulose membrane (Osmonics, Westborough, MA, USA) overnight by electroblotting. Ponceau S staining of the membrane was used to confirm that equal amounts of protein were transferred from each lane. The membrane was blocked with 5% nonfat milk in TBS (50 mM Tris (pH 7.5) and 150 mM NaCl). The membrane was then incubated with rabbit polyclonal SOX9 antibody (kindly provided by Dr Benoit de Crombrugghe) at a 1 : 1000 dilution for 1 h at room temperature. After washing with TBS, the membrane was incubated with goat anti rabbit IgG conjugated with horse radish peroxidase (1 : 2000 dilution) for 1 h at room temperature. The membrane was then washed with TBS twice followed by two washes with TBS containing 0.05% Tween 20 and developed using enhanced chemiluminescence (ECL) (Pierce, USA).
Detection of SOX9 mRNA by PCR cDNA was synthesized from 1 mg of total RNA using Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc., USA) with 1 mg of Oligo dT (12 -18) primer (Life Sciences, Amersham). SOX9 cDNA was amplified using 10 pmol each of the sense primer 5'-GCGTAT-GAATCTCCTGGACC-3' (nt 369 -nt 388 of GenBank accession number NM_000346) and antisense primer 5'-GCGGCTGGTACTTGTAATCC-3' (nt 902 to nt 882). GAPDH cDNA, used to determine the integrity of cDNA used for PCR, was amplified using 10 pmol each of sense primer 5'-ACC ACA GTC CAT GCC ATC AC-3' (nt 517 to nt 536 of GenBank accession number XM_065789) and antisense primer 5'-TCC ACC ACC CTG TTG CTG TA-3' (nt 938 to nt 919). PCR conditions for SOX9 and GAPDH cDNA amplification were denaturation at 948C for 30 s, annealing at 598C for 30 s and extension at 728C for 1 min for 30 cycles. PCR reactions were performed in a Perkin Elmer DNA thermal cycler and the PCR products were electrophoresed and analysed in 1.5% agarose gels.
Plasmids
Full-length SOX9, cloned into the HindIII-EcoRI sites of pCDMA (modified version of pcDM8 plasmid from Invitrogen), a 5'-N-terminal Flag tagged SOX9 cDNA (codon 27 -509) cloned into the BamHI-EcoRI site of pcDNA3, and a Cterminal truncated SOX9 (SOX9-DN) (codon 27 -304) cloned into the BamHI-SmaI site of pcDNA3 were provided by Dr Benoit de Crombrugghe's laboratory (Lefebvre et al., 1997) . The C-terminal truncated SOX9 lacks the transactivation domain but retains the SOX9 DNA binding domain and has been reported to function as a dominant negative inhibitor of wild type SOX9 (Lefebvre et al., 1997) . A GFP-SOX9 expression vector was constructed to analyse the effect of SOX9 on the cell cycle. 5' Flag tagged SOX9 cDNA was cloned, in frame, into the BglII-EcoRI site of pEGFP-C1 (Clontech). A dominant negative GFP-SOX9 (GFP-SOX9-DN) was generated by cleaving pEGFP-SOX9 with SmaI and religating the plasmid to remove the C-terminal transactivation domain. A SOX9 CAT reporter was constructed by cloning the SOX9 response sequence (4648) from (4648)-p89-Luc (Lefebvre et al., 1997) into the HindIII site of DMTV-CAT to form DMTV-(4648)-CAT. DMTV-CAT contains the basal promoter of the mouse mammary tumor virus LTR and has been previously used in many of our studies (Forman et al., 1992) .
Transient transfection
T-47D cells were plated at a density of 0.2610 6 cells/well in 6-well tissue culture plates. The cells were transfected with 3 to 5 mg of GFP-SOX9 or GFP-SOX9-DN using Genefect transfection reagent (Mediatech, USA). Briefly, cells were transfected with plasmid DNA in 0.8 ml serum free medium for approximately 5 h, following which 1 ml of medium containing 20% fetal calf serum was added and left to incubate overnight. Fresh medium containing 10% FCS was added the following day. Cells were harvested 48 -72 h later and analysed for cell cycle changes by flow cytometry. The biologic activity of GFP-SOX9 and GFP-SOX9-DN in T-47D cells was determined in transfections using DMTV-(4648)-CAT and the cells were harvested 48 h later for CAT activity (Forman et al., 1992) .
Cell cycle analysis
Cells were harvested using trypsin-EDTA for about 2 min and then centrifuged at 1500 r.p.m. for 5 min. The cells were then washed twice with PBS and the washed cell pellet was fixed with ice-cold 70% ethanol overnight at 7208C. Cells were then centrifuged and washed once with PBS. For cell cycle analysis, the ethanol-fixed cells were re-suspended in staining solution (50 mg/ml propidium iodide (PI) and 100 mg/ml RNase A in PBS). Samples were stored at 48C in the dark for at least 1 h prior to analysis. Flow cytometric analysis for GFP and PI was performed using a four-color FACScan (Becton-Dickson Immunocytometry Systems, San Jose, CA, USA). GFP positive cells were analysed for cell cycle changes. GFP negative cells in the same transfection were also analysed for cell cycle changes and served as an internal control for each experiment.
Mice
Male and female C57BL/6 mice were obtained from Taconic Farms and housed in separate cages. Mice were injected daily with 150 mg of RA dissolved in canola oil or with canola oil alone for 4 days. Control and treated mice were housed in separate cages. The mice were sacrificed after 96 h of treatment. We obtained breast, kidney, and liver from male and female mice as well as testicular tissue from male mice. RNA was isolated from the tissues with Trizol reagent (GIBCO-BRL). Tissue expression of SOX9 was determined by RT -PCR as described above in Materials and methods.
